WHS Recognizes Eluciderm, Inc. with Industrial R&D Award for Research on ELU42 Mechanism of Action
Summary: Eluciderm, Inc. received the Wound Healing Society’s Industrial Research & Development Poster Presentation Award at SAWC Spring 2026 for work on ELU42, a first-in-class topical small-molecule PARP-signaling modulator with bacteriostatic properties. Preliminary data from the first five diabetic foot ulcer (DFU, Wagner Grade 1–2) patients in the ongoing Phase I/IIA SuperHealer42 study showed mean wound area reduction of 40.9% at one week and 86.0% at four weeks, with excellent local tolerability and no treatment-related serious adverse events. Preclinical mechanistic studies (RNA-seq, immunostaining in murine models) demonstrated early suppression of pro-fibrotic genes, subsequent angiogenic activity, and recruitment of SOX9-positive stem cells, supporting a “restorative reset” that favors regenerative rather than scar-mediated healing. ELU42 has potential across chronic wounds, burns, and other indications.
Key Highlights:
- 86.0% mean DFU area reduction at 4 weeks in early clinical data
- Mechanism: PARP modulation suppresses fibrosis, mobilizes reparative stem cells
- WHS Industrial R&D Award at SAWC 2026; second major award for ELU42
- Good safety profile with undetectable systemic absorption
Keywords: ELU42, diabetic foot ulcer healing, PARP signaling, Eluciderm